![paragon trial hfpef paragon trial hfpef](https://cdn.sanity.io/images/0vv8moc6/ajmc/969a36d3987bc30f8714f2da931b103585dcbfd8-1280x720.jpg)
![paragon trial hfpef paragon trial hfpef](http://52in52.goodybedside.georgetown.domains/wp-content/uploads/2020/07/VAbst_PARAGON-HF_NEJM2019.png)
In a previous HFpEF epidemiology study, the survival of patients with. The study then compares baseline HRQL with patients with heart failure with reduced ejection fraction (HFrEF) (≤40%) enrolled in the PARADIGM-HF (Prospective Comparison of ARNI with an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. mortality.4 The survival of HFpEF is poor, particularly after hospitalization for HF. The study reports comprehensive baseline HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) administered at randomization after active run-in period. Objectives The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction) trial is designed to determine the efficacy and safety of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction (HFpEF). The PARAGON-HF trial randomized symptomatic patients with HFpEF (≥45%) ≥50 years of age to either sacubitril/valsartan or valsartan. Effects of Sacubitril-Valsartan, Versus Valsartan, in Women Compared to Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF.
![paragon trial hfpef paragon trial hfpef](https://www.researchgate.net/publication/347044376/figure/tbl1/AS:1002747293863937@1616084993210/Comparison-of-PARAGON-HF-CHARM-P-TOPCAT-trials-on-left-ventricular-ejection-fraction.png)
There are limited data characterizing HRQL in patients with HFpEF using validated metrics. Is PARAGON a Paragon Example of an HFpEF Clinical Trial A Call for Deep Phenotyping. This study sought to describe baseline health-related quality of life (HRQL) in the PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HFpEF) trial, the largest heart failure with preserved ejection fraction (HFpEF) trial to date.